PET scan trial using two tracers at once
Part of Brain & nervous system, Cancer, Kidney & urinary clinical trials.
This trial tests a new PET/CT imaging method that uses two different tracers at the same time to better see cancers and Parkinson's syndrome. It may help doctors find and monitor disease more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You either are healthy, or have prostate cancer, neuroendocrine tumor, glioma, or Parkinson's syndrome.
- If healthy, your weight and height fall within a specific range (body mass index between 19 and 26).
- You are not pregnant or breastfeeding, and do not work with radiation.
- You have no serious heart, lung, kidney, or other major health problems, and haven't had recent radiation or certain treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new type of PET scanner (called J-PET) to see if it works as well as current PET/CT machines. If you are already scheduled for a whole-body PET/CT scan, participating would mean your scan is done with this experimental scanner instead.
This trial uses a special imaging scan (SPECT/CT) with a small amount of radioactive tracer to look at prostate cancer. It aims to see how well the scan matches your prostate cancer tests and may help improve detection and assessment.
This trial uses special PET imaging to see where progressive prostate cancer is in the body—one tracer to look at general sugar use and one designed to detect testosterone-related activity. It may help doctors better map cancer spread so future treatment planning can be more targeted.
This trial compares two types of PET scans—one using a new tracer called [18F]F-PSMA-N5 and another using an existing tracer called [68Ga]Ga-PSMA-11—to see which is better at finding prostate cancer, including early signs of recurrence. If you have or are suspected of having prostate cancer, this study may help determine how advanced the disease is.
This study tests a new imaging agent (68Ga-NYM032) used with PET/CT scans to help doctors better detect prostate cancer before surgery. If you have biopsy-confirmed prostate cancer and are planning to have your prostate removed, this trial may help evaluate whether this new imaging method improves cancer detection.
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Hear when a new Prostatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.